Eastgate Biotech Company Description
Eastgate Biotech Corp., a development stage company, develops novel formulations of natural compounds and pharmaceutical products.
The company is developing pharmaceutical products, such as Lorazepam oral spray for acute seizures emergency treatment; Ketoconazole 2% topical ointment for treatment of skin fungal infections; and Metformin chewable/ sublingual tablets for treatment of type 2 diabetes.
It is also developing natural products and dietary supplements, including E-drops Nano and PURALEN that are self-nanoemulsifying compositions containing natural essential oils for oral administration; Glucora, a soft gelatin capsule with Banaba extract in self-emulsifying formulation for oral administration; URBAN POWER, a soft gelatin capsule with Ursolic acid and Banaba extract in self-emulsifying formulation for oral administration; Vitamin D3 nanoemulsion, a nanoemulsion with cholecalciferol; and Cleanezze, a hand sanitizer containing oil.
Eastgate Biotech Corp. has collaboration with Biotech Corp. to develop a vaccine against COVID-19. The company was formerly known as Eastgate Acquisitions Corporation and changed its name to Eastgate Biotech Corp. in December 2014.
Eastgate Biotech Corp. was founded in 1999 and is based in Toronto, Canada.
| Country | United States |
| Founded | 1999 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 3 |
| CEO | Rosella Perri |
Contact Details
Address: 65 Harbour Square Toronto, Nevada M5J 2L4 Canada | |
| Phone | 647-692-0652 |
| Website | EastGateBiotech.com |
Stock Details
| Ticker Symbol | ETBI |
| Exchange | OTCMKTS |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US2772531008 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Rosella C. Perri | Chief Executive Officer, Secretary, Treasurer and Director |
| William D. Abajian | Vice Chairman, President and Chief Operating Officer |
| Dr. Joseph Schwarz Ph.D. | Chief Scientific Officer |